Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Abbott raises earnings outlook after surpassing Q3 estimates

EditorAmbhini Aishwarya
Published 30/10/2023, 07:10
© Reuters
ABT
-

Abbott has raised its earnings outlook for the full year 2023 to between $4.42 and $4.46 per share, up from the previous range of $4.30 and $4.40, after reporting Q3 revenues of $10.1 billion and adjusted earnings of $1.14 per share. These figures surpassed street estimates despite marking a 2.6% year-on-year decline.

The company's Q3 revenue was characterized by a rise in sales across multiple segments, including Medical Devices (17%), Nutrition (16%), and Established Pharmaceuticals (3%). However, the Diagnostics segment experienced a significant fall in revenues (33%) due to lower demand for COVID-19 testing. This was offset partially by a 10.1% rise in revenues excluding COVID-19 tests.

Despite lower revenues and a contraction in the adjusted operating income margin to 22.9%, Abbott reported only a 1% decline in the bottom line to $1.14 on a per-share and adjusted basis in Q3'23. This was attributed to lower taxes and a 1% decline in total shares outstanding.

Lastly, Abbott does not perceive GLP-1 drugs as a threat to their FreeStyle range of CGM devices, contrasting with the Trefis High Quality (HQ) Portfolio which has consistently outperformed the S&P 500, providing better returns with less risk.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.